Latest news
Loading news…
Ducentis BioTherapeutics
ClosedOperating status — whether the company still runs independently. “Closed” usually means it was acquired, merged, or shut down.🔥 LowHeat score — how much recent activity & attention the company has (web traffic, news, hiring). Witney, Oxfordshire, United Kingdom Founded 2015 1-10 employees For Profit
Ducentis is a pre-clinical stage company that aims to develop novel therapies for inflammation and autoimmune disease.
Ducentis BioTherapeutics was acquired by Arcutis Biotherapeutics in 2022 for $400M.
Total Funding
Available in Pro Last Funding
Available in Pro Acquisitions
0
Monthly Visits
Available in Pro Contacts
0
Patents
6
Company Details
Funding & Financials
Pro- Total funding
- Funding rounds
- Last funding
- Last funding type
- Last funding date
- Funding status
- Total equity funding
- Revenue range
IPO & Stock
- IPO status
- Private
Web Traffic
Pro- Monthly visits
- Global traffic rank
- 6-mo avg visits
- Visit duration (s)
- Pages / visit
- Bounce rate
- Rank change (mo)
Technology & IP
- Active technologies
- 7
- Patents granted
- 6
- Trademarks
- 0
- Top patent class
- Medical Or Veterinary Science; Hygiene
- IT spend
- $9M
Company Info
- Founded
- 2015
- Employees
- 1-10
- Operating status
- Closed
- Company type
- For Profit
- Org types
- company
- Founders
- 2
- News articles
- 6
- HQ
- Witney, Oxfordshire, United Kingdom
- Region
- Europe, Middle East, and Africa (EMEA)
- Exit date
- Sep 7, 2022
Signals & Scores
- Heat score
- Low
- Trend (7d)
- 0
- Trend (30d)
- 1
- Trend (90d)
- 1.4
Key People at Ducentis BioTherapeutics
Co-founder, CEO
Explore 200,000+ acquisitions — free
Filter the full database across sectors, companies, dates, and deal sizes. No signup, no paywall.
Recent News related to Ducentis BioTherapeutics
Loading news…
FAQs about Ducentis BioTherapeutics
People who checked this page also checked these
Browse the full Acquirezy directory.